Pure Global
NCT05680844

Peripheral Treg Cell Senescence & Serum Total Cholesterol Level

Observational Study of the Correlation Between Peripheral Treg Cell Senescence and Serum Total Cholesterol Level
Tianjin Medical University·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hypercholesterolemia
Study type
Observational
Sponsor & location
Primary sponsor
Tianjin Medical University
Location
Tianjin, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2023
End date
Mar 31, 2023
Enrollment
200 participants
Primary outcome

Treg cell senescence

Summary

Hypercholesterolemia is a risk factor for the occurrence and development of atherosclerosis.
 Recent animal studies have found that increased serum cholesterol level is associated with
 peripheral Treg cell senescence, but clinical evidence is still lacking. The purpose of this
 study is to analyze the correlation between human peripheral Treg cell senescence and serum
 total cholesterol level using clinical blood samples, thus laying a foundation for the
 establishment of novel therapeutic strategies for atherosclerosis based on the regulation of
 Treg cell senescence.

ICD-10 classifications
Pure hypercholesterolaemiaLipoprotein deficiencyHyperglycaemia, unspecifiedDisorders of lipoprotein metabolism and other lipidaemiasOther disorders of lipoprotein metabolism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05680844
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05680844 through Pure Global AI's free database. This phase not specified trial is sponsored by Tianjin Medical University and is currently Recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.